Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

New Study Indicates Xarelto Leads to Fewer Stroke-Related Deaths Than Warfarin

By The Janssen Pharmaceutical Companies of Johnson & Johnson | November 13, 2018

New findings from a study of 20,000+ people presented November 10 at the 2018 American Heart Association meeting showed that non-valvular atrial fibrillation (AFib) patients taking Xarelto (rivaroxaban) experienced significantly fewer strokes compared to those taking warfarin, according to Janssen Pharmaceutical Companies of Johnson & Johnson. 

Specifically, Xarelto reduced overall stroke by 27 percent, stroke severity by 62 percent, and 30-day post-stroke mortality by 64 percent.

“These data are a great complement to clinical evidence to ensure medicines perform as expected,” Dr. JoAnne Foody, executive director, medical affairs-cardiovascular at Janssen Inc., said. “With Xarelto showing clear and meaningful benefits over warfarin, we believe physicians will consider these findings when deciding how to manage patients with non-valvular AFib.”

Up to six million Americans have AFib, which puts them at an increased risk of stroke1, and one of three people with AFib will have a stroke at some point during their life2. Treatment guidelines currently recommend oral anticoagulants for stroke prevention in people with non-valvular AFib.

Xarelto remains the most studied oral Factor Xa inhibitor in the world today with more than 200,000 people evaluated in published real-world research since its approval, according to Janssen. Post-marketing studies and registries continue to confirm the safety and efficacy of Xarelto in routine clinical use across a broad spectrum of patients.

(Source: Janssen Pharmaceutical Companies of Johnson & Johnson)

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE